2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1002

Pneumocystis Jiroveci in Rheumatic Disease: A 20 Year Single-Center Experience
Abstract Number: 1003

Ultrasonography Changes during the Course of Septic Arthritis ARE Associated with Functional Outcome
Abstract Number: 1004

Herpes Zoster Virus Infection in Patients Treated with Biological Therapies (BIOBADASAR)
Abstract Number: 1005

Biallelic Hypomorphic Mutations in a Linear Deubiquitinase Define Otulipenia, an Early-Onset Systemic Autoinflammatory Disease
Abstract Number: 1006

Immune Complex-Mediated TLR8 Activation Shifts Neutrophils from Phagocytosis to Netosis through Furin-Dependent Shedding of Fcgriia
Abstract Number: 1007

Interferon Regulatory Factor 1 Is the Key Driver of Inflammasome Activity in Systemic Lupus Erythematosus
Abstract Number: 1008

Advantageous Effect of an Endogenous Retroviral Envelope Protein in Systemic Lupus Erythematosus with Ex Vivo and In Vivo Anti-Inflammatory Potential
Abstract Number: 1009

Plasmacytoid Dendritic Cells Are Activated in Systemic Sclerosis and Contribute to the Disease By Inducing Ifnα and CXCL4
Abstract Number: 1010

Elucidating the Activation Profile of Systemic Sclerosis Macrophages
Abstract Number: 1011

Correlations Between B Cell Epitope Specificity and Clinical Features in Patients with Jo-1 Antibodies and the Anti-Synthetase Syndrome
Abstract Number: 1012

WITHDRAWN
Abstract Number: 1013

The Risk of Colchicine Associated Myopathy in Gout: Influence of Concomitant Use of Statin
Abstract Number: 1014

Juvenile Dermatomyositis: What Comes Next?
Abstract Number: 1015

Pro-Inflammatory Cytokines Produced By Different Subsets of Peripheral Blood Mononuclear Cells Are Associated with Ro52/TRIM21 Deficiency in Patients with Inflammatory Myopathies
Abstract Number: 1016

Soluble BAT-3: A New Biomarker for Antisynthetase Syndrome

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].